Minimal Change in CAR T Cell Manufacturing Can Impact in Expansion and Side Effect of the CAR T Cell Therapy
Francesco Ceppi(University of Lausanne), Michael C. Jensen(Seattle Children's Hospital), Qian Wu(Cancer Research Center), Stephanie Rhea, Isaac Jenkins(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Corinne Summers(Seattle Children's Hospital), Rebecca Gardner(Seattle Children's Hospital), Alan S. Wayne(University of Southern California), Olivia Finney(Seattle Children's Hospital), Colleen Annesley(Unknown), Michael A. Pulsipher(Primary Children's Hospital), Wen Yang(Seattle Children's Hospital), Julie R. Park(Seattle Children's Hospital)
Cited by 6
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k